News & Trends - Pharmaceuticals
Moving the needle from intention to action: Positioning patients as strategic partners in health policy

As Australia nears a federal election, the question of patient advocacy in health policy has never been more pressing. In this Health Industry Hub pre-election senior leadership series, Deidre MacKechnie, CEO of Australian Patient Advocacy Alliance (APAA) and Leanne Raven, Chair of APAA and CEO of Crohn’s and Colitis Australia (CCA), challenge the inertia that has kept patient perspectives on the periphery rather than at the core of health policy decisions.
Over the past five years, the patient voice has gained momentum, but the reality remains stark: patient perspectives are still not structurally integrated into health policy and Health Technology Assessment (HTA) decision-making. Without it, policies continue to be disconnected from the very people they are designed to serve.
A recent international study of HTA representatives, including those from Australia, exposes a troubling contradiction. While the theoretical value of patient input is widely accepted, HTA committees continue to question its “genuine value” and how it can be practically incorporated. So, what is required of government to move the needle from intention to action?
Another study suggests that HTA bodies expect patient advocacy groups – often the most under-resourced organisations – to take on the responsibility of generating and submitting patient preference data. But should they bear this burden alone?
The medical community and specialty societies have a pivotal role in shaping the narrative, ensuring that patient experiences are not seen as anecdotal but as indispensable data when it comes to HTA decision-making.
With an election looming, what steps should be taken next to advance the goal of positioning patients as strategic partners in health policy?
In reimagining healthcare across the entire patient journey, Health Industry HubTM is the only one-stop-hub uniting the diversity of the Pharma, MedTech, Diagnostics & Biotech sectors to inspire meaningful change.
The Health Industry HubTM content is copyright protected. Access is available under individual user licenses. Please click here to subscribe and visit T&Cs here.
News & Trends - Pharmaceuticals

Clinicians shift stance, join calls for PBS subsidy of obesity and weight-loss medicines
Over a third of Australian adults live with obesity, and the National Obesity Strategy estimates the direct and indirect costs […]
MoreNews & Trends - Pharmaceuticals

Astellas secures new indication for prostate cancer drug
Astellas Xtandi (enzalutamide) is now TGA registered for a new indication for patients with non-metastatic hormone-sensitive prostate cancer (nmHSPC) with […]
MoreNews & Trends - MedTech & Diagnostics

Stakeholder calls intensify as government stalls on genetic discrimination ban
Calls have intensified for the federal government to honour its commitment to outlaw genetic discrimination in life insurance, as stakeholders […]
MoreNews & Trends - MedTech & Diagnostics

Pressure mounts to expand home-based therapies in kidney disease: World Kidney Day
As Australia marks World Kidney Day, the stark reality is that one in three adults is at risk of chronic […]
More